Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
United European Gastroenterol J
; 7(7): 908-913, 2019 08.
Article
in En
| MEDLINE
| ID: mdl-31428415
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Direct Service Costs
/
Gastrointestinal Agents
/
Inflammatory Bowel Diseases
/
Tumor Necrosis Factor-alpha
/
Cost of Illness
/
Adalimumab
/
Infliximab
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
United European Gastroenterol J
Year:
2019
Document type:
Article
Affiliation country:
France